EF-001 is under clinical development by Everfront Biotech and currently in Phase II for Anaplastic Astrocytoma. According to GlobalData, Phase II drugs for Anaplastic Astrocytoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EF-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
For a complete picture of EF-001’s drug-specific PTSR and LoA scores, buy the report here.